An artemisinin derivative for the Treatment of CMV Viral Infections.
Sector: Infectious Diseases-Microbiology-Virology
Novel approach for the treatment of Cytomegalovirus (CMV) infection. The technology addresses unmet medical need in the field of CMV management. The use of currently available anti-CMV drugs is limited due to toxicity, low oral bioavailability and drug resistance.
We have a pre- clinical proof of concept demonstrating the utility of a small molecule as an anti-viral agent (NDA will be required to disclose the identity of our candidate compound). The compound was also proven to be safe and efficacious in a phase I-II clinical study conducted by a major biopharmaceutical company for another indication.
Indications / Applications:
Treatment and prevention of human cytomegalovirus infection. Prophylaxis & treatment in transplant patients. Treatment of symptomatic and asymptomatic congenital infection. Prevention of maternal-fetal transmission in pregnant woman. Treatment of symptomatic infection in healthy individuals.
Novel, orally administered, potent and safe, anti - HCMV drug for the prevention and treatment of HCMV infection.